	US 12,072,339 B2
	Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment and diagnosis of mood disorders
Jae Young Seong, Seoul (KR); Byung Joo Ham, Seoul (KR); Min-Hyeok Lee, Seoul (KR); and Nui Ha, Gyeonggi-do (KR)
Assigned to Neuracle Science Co., Ltd., Seoul (KR)
Appl. No. 16/753,295
Filed by Neuracle Science Co., Ltd., Seoul (KR)
PCT Filed Oct. 2, 2018, PCT No. PCT/IB2018/057646 § 371(c)(1), (2) Date Apr. 2, 2020, PCT Pub. No. WO2019/069229, PCT Pub. Date Apr. 11, 2019.
Claims priority of provisional application 62/566,877, filed on Oct. 2, 2017.
Claims priority of provisional application 62/582,888, filed on Nov. 7, 2017.
Prior Publication US 2020/0300870 A1, Sep. 24, 2020
Int. Cl. G01N 33/68 (2006.01); C07K 16/24 (2006.01); C12Q 1/6883 (2018.01)

CPC G01N 33/6896 (2013.01) [C07K 16/24 (2013.01); C12Q 1/6883 (2013.01); C07K 2317/622 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/304 (2013.01)]

14 Claims

1. A method of determining a FAM19A5 protein level in a subject having a mood disorder comprising detecting whether the FAM19A5 protein level from a biological sample obtained from the subject is higher compared to a corresponding level from a normal control,

wherein the detecting comprises contacting the biological sample with an antibody or an antigen-binding fragment thereof that specifically binds to a FAM19A5 protein (anti-FAM19A5 antibody) and measuring the FAM19A5 protein level in the biological sample, and

wherein the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3, wherein the heavy chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 14, 15, and 16, respectively, and the light chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs:

26, 27, and 28, respectively.